跳至主要内容
临床试验/2025-521324-29-00
2025-521324-29-00招募中2 期

[⁶⁸Ga]Ga-HKG301 PET/CT for staging and restaging patients with primary breast cancer: a phase II study (FAPILOUS)

Odense University Hospital1 个研究点 分布在 1 个国家目标入组 65 人开始时间: 2026年10月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
招募中
入组人数
65
试验地点
1
主要终点
Sensitivity, specificity, predictive values, and accuracy for primary staging and restaging breast cancer with [⁶⁸Ga]Ga-HKG301 PET/CT

研究概览

简要总结

The main objective is to evaluate the efficacy of [⁶⁸Ga]Ga-HKG301 PET/CT in staging and restaging patients with newly diagnosed breast cancer.

入排标准

年龄范围
18 years 至 65+ years(65+ Years, 18-64 Years)
接受健康志愿者

入选标准

  • Male and females ≥18 years
  • Biopsy-verified newly diagnosed primary breast cancer
  • Can read and understand Danish
  • Capable of providing written and informed consent
  • Undergoing a routine [¹⁸F]FDG PET/CT scan as part of the clinical standard diagnostic workup

排除标准

  • Pregnant or lactating women
  • Not able to participate in scan
  • Ongoing oncological treatment for another cancer
  • History of allergic reactions / hypersensitivity attributed to [⁶⁸Ga]Ga-HKG301

研究组 & 干预措施

AAA514

Test

干预措施: AAA514 (Drug)

结局指标

主要结局

Sensitivity, specificity, predictive values, and accuracy for primary staging and restaging breast cancer with [⁶⁸Ga]Ga-HKG301 PET/CT

Sensitivity, specificity, predictive values, and accuracy for primary staging and restaging breast cancer with [⁶⁸Ga]Ga-HKG301 PET/CT

次要结局

  • The correlation between the response measures observed on [⁶⁸Ga]Ga-HKG301 PET/CT and the histopathological response
  • The influence of [⁶⁸Ga]Ga-HKG301 PET/CT on stage migration, alterations in treatment decisions, and incidental findings
  • Evaluate safety and tolerability of [⁶⁸Ga]Ga-HKG301

研究者

申办方类型
Hospital/Clinic/Other health care facility
责任方
Principal Investigator
主要研究者

Sara Dahlsgaard-Wallenius

Scientific

Odense University Hospital

研究点 (1)

Loading locations...

相似试验